Iovance Biotherapeutics, Inc.
NEWS
As the city rapidly develops as a biopharma hub, wet lab space is rapidly dwindling.
Study: Adoptive cell transfer of tumor-infiltrating lymphocytes (ACT-TILs) is more effective in patients who have not been treated with checkpoint inhibitors than in those who have undergone one or more therapies.
Approximately 14,000 American women are expected to be diagnosed with invasive cervical cancer in 2021, and more than 4,000 are expected to succumb to the disease.
Life sciences news sometimes flies under the radar. So here’s a look at a few stories you may have missed.
Maria Fardis, who has been with the company since 2016, stepped down as CEO following FDA’s delay on its Biologics License Application.
The FDA further delays Iovance’s filing for its TIL therapy as it requests additional data on the treatment’s potency assays.
Data on multiple oncology therapeutic programs are being unveiled ahead of the start of the annual American Association for Cancer Research meeting, which will be held virtually this year due to the ongoing COVID-19 pandemic.
Female leaders in the biopharma industry may further promote diversity and inclusion at the workplace and serve as role models for young female professionals. Here is a list of 16 of the highest-paid female CEOs in biopharma.
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
JOBS
IN THE PRESS